Numeta G19e (Valine, Ornithine Hydrochloride, Alanine, Arginine, Cysteine, Histidine, Isoleucine, Leucine, Methio)

Numeta G19e is used in clinical nutrition to address amino acid requirements in patients with complex metabolic needs.

• Critical care patients: provides balanced amino acids to support protein synthesis and nitrogen balance.
• Neonatal intensive care: supplies essential amino acids for growth and development in preterm infants.
• Post‑surgical recovery: aids in tissue repair and immune function through comprehensive amino acid provision.
• Chronic kidney disease management: assists in maintaining nutritional status while limiting nitrogen waste.
• Severe malnutrition: contributes to re‑establishment of lean body mass during nutritional rehabilitation.

• Numeta G19e delivers a mixture of essential and non‑essential amino acids directly into the bloodstream, bypassing gastrointestinal absorption. The amino acids serve as substrates for protein synthesis, support gluconeogenesis, and help maintain nitrogen balance, thereby sustaining cellular metabolism and tissue repair in patients unable to meet nutritional needs orally or enterally.

Numeta G19e may be associated with infusion‑related reactions and metabolic disturbances.

Common Side Effects

• Mild hyperglycaemia: transient rise in blood glucose during infusion.
• Electrolyte shifts: minor changes in potassium or phosphate levels.
• Local irritation: redness or discomfort at the infusion site.
• Nausea: occasional feeling of queasiness during or after infusion.
• Headache: mild headache reported by some patients.

Serious or Rare Side Effects

• Severe hypersensitivity: rash, bronchospasm, or anaphylaxis.
• Metabolic acidosis: significant drop in blood pH.
• Hyperosmolar reactions: fluid overload or pulmonary edema.
• Thrombophlebitis: inflammation of the vein with clot formation.
• Sepsis: infection related to catheter or infusion equipment.

Before initiating Numeta G19e, assess patient-specific factors and monitor relevant parameters.

• Renal impairment: adjust infusion rate and monitor nitrogen waste.
• Hepatic dysfunction: observe liver function tests and ammonia levels.
• Fluid balance: track input/output to avoid overload.
• Electrolyte monitoring: check serum potassium, phosphate, and calcium regularly.
• Glycaemic control: monitor blood glucose in diabetic or stress‑hyperglycaemic patients.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Numeta G19e can interact with other intravenous solutions and medications that affect electrolyte or fluid balance.

Major Interactions (Avoid)

• High‑dose potassium chloride: may cause dangerous hyperkalaemia when combined with amino‑acid solutions.
• Calcium‑containing solutions: risk of precipitation when mixed directly with amino‑acid admixtures.

Moderate Interactions (Monitor Closely):

• Diuretics: may amplify electrolyte shifts, requiring closer monitoring.
• Insulin therapy : adjust insulin dosing to account for glucose‑‑ in‑ the infusion of am‑  

-    -   """"  " " " " " "" " "" " " "" " " " "" " " " " "" " " " "" " " " "" -  " " "  -  t  "  "